The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net revenue | 260 | - |
| Cost of revenues | 112 | - |
| Personnel-related expenses and board fees | 3,329 | - |
| Professional fees, legal, and outside services | 3,094 | - |
| Facilities and insurance | -837 | - |
| Laboratory supplies and expenses | 943 | - |
| Marketing and advertising | 97 | - |
| Travel and entertainment | 185 | - |
| Other segment items | -98 | - |
| Segment loss from operations | -6,565 | - |
| Depreciation and amortization expenses | 584 | - |
| Stock-based compensation | 521 | - |
| Change in fair value of contingent consideration | 3,378 | - |
| Impairment loss on held for sale assets | 0 | - |
| Loss from operations | -11,048 | - |
| Interest expense | -29 | - |
| Other income, net | 223 | - |
| Income taxes | 0 | - |
| Net loss | -10,854 | -16,413 |
| Depreciation and amortization expense | 584 | 1,043 |
| Amortization of intangible assets | 0 | 7 |
| Stock-based compensation | 521 | 977 |
| Equity compensation for bonus awards and consulting services | 38 | 88 |
| Change in fair value of contingent consideration | 3,378 | 3,683 |
| Impairment loss on held for sale assets | 0 | 0 |
| Unrealized currency translation losses | -170 | - |
| Accounts receivable | -254 | -1,101 |
| Inventories | -222 | 283 |
| Prepaid expenses and other assets | -65 | 189 |
| Accounts payable and accrued liabilities | 1,177 | -2,086 |
| Operating lease assets and liabilities | -57 | -65 |
| Net cash used in operating activities | -4,502 | -12,137 |
| Machinery and equipment purchases, and construction in progress | 1,050 | 656 |
| Net cash used in investing activities | -1,050 | -656 |
| Proceeds from sale of common shares | 0 | 29,143 |
| Financing costs to issue common shares | 0 | 487 |
| Proceeds from sale of common shares under at-the-market transactions | 0 | - |
| Financing costs for at-the-market sales | 0 | - |
| Redemption of series a redeemable convertible preferred shares | 0 | 0 |
| Repayment of financing lease obligations | 120 | 212 |
| Net provided by financing activities | -120 | 28,444 |
| Effect of exchange rate changes on cash and cash equivalents | -105 | - |
| Net change in cash, cash equivalents and restricted cash | -5,777 | 15,651 |
| Cash and cash equivalents at beginning of period | 10,336 | - |
| Cash and cash equivalents at end of period | 20,210 | - |
Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. (IMDX)